William J Mackillop
Overview
Explore the profile of William J Mackillop including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
1897
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karim S, Mackillop W, Brennan K, Peng Y, Siemens D, Krzyzanowska M, et al.
Cancer Med
. 2019 Sep;
8(14):6258-6271.
PMID: 31472011
Background: Identifying optimal chemotherapy (CT) utilization rates can drive improvements in quality of care. We report a benchmarking approach to estimate the optimal rate of perioperative CT for muscle-invasive bladder...
2.
Karim S, Booth C, Brennan K, Peng Y, Siemens D, Krzyzanowska M, et al.
Cancer Med
. 2019 Aug;
8(12):5590-5599.
PMID: 31407518
Background: Identifying optimal chemotherapy utilization rates can drive improvements in quality of care. We report a benchmarking approach to estimate the optimal rate of adjuvant chemotherapy (ACT) for stage III...
3.
Booth C, Karim S, Mackillop W
Nat Rev Clin Oncol
. 2019 Feb;
16(5):312-325.
PMID: 30700859
The use of data from the real world to address clinical and policy-relevant questions that cannot be answered using data from clinical trials is garnering increased interest. Indeed, data from...
4.
Wei X, Siemens D, Mackillop W, Booth C
Can Urol Assoc J
. 2018 Oct;
13(4):92-101.
PMID: 30273116
Introduction: Definitive treatment for muscle-invasive bladder cancer includes either cystectomy or radiotherapy (RT). We describe use of RT and radiation oncology (RO) referral patterns in the contemporary era. Methods: The...
5.
Jin C, Kong W, Mackillop W
Radiother Oncol
. 2018 Jun;
128(3):541-547.
PMID: 29934108
Background And Purpose: Estimates of appropriate treatment rates are required for monitoring and improving access to cancer care. Optimal utilization rates for palliative radiotherapy (PRT) for patients with non-small cell...
6.
Rosenblatt E, Fidarova E, Zubizarreta E, Barton M, Jones G, Mackillop W, et al.
Radiother Oncol
. 2018 Jun;
128(3):400-405.
PMID: 29859755
Background: The planning of national radiotherapy (RT) services requires a thorough knowledge of the country's cancer epidemiology profile, the radiotherapy utilization (RTU) rates and a future projection of these data....
7.
Leveridge M, Siemens D, Brennan K, Izard J, Karim S, An H, et al.
Cancer
. 2018 Apr;
124(13):2724-2732.
PMID: 29660851
Background: Treatment guidelines for early-stage testicular cancer have increasingly recommended de-escalation of therapy with surveillance strategies. This study was designed to describe temporal trends in routine clinical practice and to...
8.
McLaughlin P, Kong W, de Metz C, Hanna T, Brundage M, Warde P, et al.
Radiother Oncol
. 2018 Feb;
127(1):143-149.
PMID: 29478762
Background And Purpose: The scope and effect of radiation oncology (RO) outreach activities within centralized radiotherapy (RT) systems is poorly defined. The purpose of this study was to describe the...
9.
Walker M, Doiron R, French S, Brennan K, Feldman-Stewart D, Siemens D, et al.
Bladder Cancer
. 2018 Feb;
4(1):49-65.
PMID: 29430507
Background: Utilization of chemotherapy for patients with muscle-invasive bladder cancer (MIBC) is low. In earlier qualitative work we used the Theoretical Domains Framework (TDF) to determine barriers and enablers of...
10.
Walker M, Doiron R, French S, Feldman-Stewart D, Siemens D, Mackillop W, et al.
Can Urol Assoc J
. 2018 Jan;
12(4):E182-E190.
PMID: 29319482
Introduction: Use of chemotherapy for muscle-invasive bladder cancer (MIBC) is known to be low. To understand factors driving practice we use the Theoretical Domains Framework (TDF) to identify barriers and...